We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Buprenorphine Maintenance for Opioid Addicts - 2

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00000203
First Posted: September 21, 1999
Last Update Posted: July 25, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Yale University
  Purpose
The purpose of this study is to evaluate varying doses of buprenorphine for opioid dependence and cocaine abuse.

Condition Intervention Phase
Opioid-Related Disorders Drug: Buprenorphine Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Buprenorphine Maintenance for Opioid Addicts

Resource links provided by NLM:


Further study details as provided by Yale University:

Primary Outcome Measures:
  • Drug use
  • Withdrawal symptoms
  • Psychological symptoms

Estimated Enrollment: 0
Study Start Date: August 1988
Study Completion Date: May 2006
Primary Completion Date: May 2006 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Please contact site for information.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000203


Locations
United States, Connecticut
VA Connecticut Healthcare System
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
Yale University
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Thomas R Kosten, M.D. VA Connecticut Healthcare System
  More Information

Publications:
Responsible Party: Yale University
ClinicalTrials.gov Identifier: NCT00000203     History of Changes
Other Study ID Numbers: NIDA-05626-2
R01DA005626 ( U.S. NIH Grant/Contract )
R01-05626-2
First Submitted: September 20, 1999
First Posted: September 21, 1999
Last Update Posted: July 25, 2013
Last Verified: August 2005

Additional relevant MeSH terms:
Opioid-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Buprenorphine
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists